Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea-Reference-Cited by-同舟云学术

Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea

Published:2024 Issue: Volume:39 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Choi Young-Sook¹^ORCID,Ryu Sukhyun²^ORCID,Kim Ryu Kyung³^ORCID,Chiara Achangwa²^ORCID,Baek Soojin¹^ORCID,Nam Hojin¹^ORCID,Park Eunkyung¹^ORCID,Kim Eun Kyoung¹^ORCID,Choe Young June⁴^ORCID,Kwon Donghyok¹^ORCID,Choi Won Suk⁵^ORCID

Affiliation:

1. Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.

2. Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

3. Korea Insurance Development Institute, Seoul, Korea.

4. Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

5. Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea.

Funder

Korea National Institute of Health, Korea Disease Prevention Agency

Government-wide R&D to Advance Infectious Disease Prevention and Control, Republic of Korea

National Research Foundation of Korea

Publisher

XMLink

Link

https://jkms.org/pdf/10.3346/jkms.2024.39.e258

Reference15 articles.

1. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

2. Estimation of Serial Interval and Reproduction Number to Quantify the Transmissibility of SARS-CoV-2 Omicron Variant in South Korea

3. Association Between the Relaxation of Public Health and Social Measures and Transmission of the SARS-CoV-2 Omicron Variant in South Korea

4. Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

5. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States